Program overview
Context
Indication: Metastatic Colorectal Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: Gilead Sciences
IMMU 130 is flagged as registry stop signal because public records show a registry stop signal, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: Metastatic Colorectal Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: Gilead Sciences
Registry: 5/5
Timeline: 1/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 4/5
https://clinicaltrials.gov/study/NCT01915472
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT01915472 | Registry Stop Signal (WITHDRAWN) | stale_update_signal | Low Signal | rare_population_signal | strict_eligibility_signal |